Journal of Clinical Immunology

, Volume 34, Issue 2, pp 181–193 | Cite as

Autoantibodies to IL-17A may be Correlated with the Severity of Mucocutaneous Candidiasis in APECED Patients

  • Adrien Katalin Sarkadi
  • Szilvia Taskó
  • Gabriella Csorba
  • Beáta Tóth
  • Melinda ErdősEmail author
  • László Maródi
Original Research


The relative roles of various autoantibodies against IL-17-type cytokines in susceptibility to chronic mucocutaneous candidiasis (CMC) in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) remain poorly defined. The purpose of this longitudinal study was to analyze the relationship between the occurrence of mucocutaneous candidiasis and levels of anti-IL-17A, anti-IL-17F and anti-IL-22 autoantibodies. We studied six APECED patients from four families with various disease manifestations. Clinical data were collected during regular follow-up. Anti-endocrine organ antibody levels and clinical chemistry and immunology parameters were determined in routine laboratory assays on freshly isolated serum. Levels of autoantibodies against IL-17A, IL-17F, IL-22, IFN-α, IFN-ω and TNF-α, and cytokine release by Candida-exposed blood cells were determined by ELISA. Mutations were analyzed by sequencing genomic DNA. Four patients carried the germline c.769C > T homozygous nonsense mutation, which results in R257X truncation of the AIRE protein, and two patients from the same family were compound heterozygous for the c.769C > T/c.1344delC mutation. We found persistently high levels of antibodies against IL-17A in the serum samples of one patient presenting CMC since infancy and low or undetectable anti-IL-17A antibody levels in the sera of five patients with no candidiasis or without severe candidiasis. By contrast, levels of autoantibodies against IL-17F and IL-22 were higher in all patients than in healthy controls. Release of IL-17-type cytokines by Candida-exposed blood mononuclear cells was low or negligible in all patients tested. We suggest that anti-IL-17A antibodies may play an important role in the predisposition to candidiasis of APECED patients. However, the lack of severe CMC in APECED patients with high levels of IL-17F and anti-IL-22 autoantibodies clearly calls into question the role of these antibodies as the principal cause of cutaneous and mucosal candidiasis in at least some APECED patients. These data also suggest that the impaired release of IL-17-type cytokines by blood cells may be an element of the immunopathology of CMC in APECED patients.


APECED IL-17 IL-22 chronic mucocutaneous candidiasis 



This work was supported by the UD Faculty of Medicine Research Fund (Bridging Fund 2012) and the TÁMOP 4.2.2.A-11/1/KONV-2012-0023 “VÉD-ELEM” project grant to LM. We thank Drs. A. B. Wolff, É. Oláh and the members of our laboratory team for helpful discussion, and to Drs. L. Gajdos, Zs. Petrekanits, and J. Boda for referring the patients.

Conflict of interest statement

The authors have no conflicts of interest.


  1. 1.
    Ahlgren KM, Moretti S, Lundgren BA, Karlsson I, Ahlin E, Norling A, et al. Increased IL-17A secretion in response to Candida albicans in autoimmune polyendocrine syndrome type 1 and its animal model. Eur J Immunol. 2011;41:235–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829–36.PubMedCrossRefGoogle Scholar
  3. 3.
    Al-Herbish AS, Bailey JD, Kooh SW. Growth hormone deficiency in autoimmune polyglandular disease type 1. Saudi Med J. 2000;21(8):765–8.PubMedGoogle Scholar
  4. 4.
    Collins SM, Dominguez M, Ilmarinen T, Costigan C, Irvine AD. Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectoderma dystrophy syndrome. Br J Dermatol. 2006;154(6):1088–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Cypowyj S, Picard C, Maródi L, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol. 2012;42(9):2246–54.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    De Luca A, Zelante T, D’Angelo C, Zagarella S, Fallarino F, Spreca A, et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. 2010;3(4):361–73.PubMedCrossRefGoogle Scholar
  7. 7.
    den Dunnen JT, Antonarakis E. Nomenclature for the description of human sequence variations. Hum Genet. 2001;109:121–4.CrossRefGoogle Scholar
  8. 8.
    Eyerich K, Foerster S, Rombold S, Seidl HP, Behrendt H, Hofmann H, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol. 2008;128(11):2640–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Gupta AN, Kaniyoor Nagri S. Schmidt’s syndrome—case report. Australas Med J. 2012;5(6):292–5.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Husebye ES, Perheentupa J, Rautemaa R, Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med. 2009;265(5):514–29.PubMedCrossRefGoogle Scholar
  11. 11.
    Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207(2):299–308.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol. 2011;41:1517–27.PubMedCrossRefGoogle Scholar
  13. 13.
    Kreuz W, Erdös M, Rossi P, Bernatowska E, Espanol T, Maródi L. A multi-centre study of efficacy and safety of intratect, a novel intravenous immunoglobulin preparation. Clin Exp Immunol. 2010;161(3):512–7.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Maródi L. Local and systemic host defense mechanisms against Candida: immunopathology of candidal infections. Pediatr Infect Dis J. 1997;16(8):795–801.PubMedCrossRefGoogle Scholar
  15. 15.
    Maródi L, Cypowyj S, Tóth B, Chernyshova L, Puel A, Casanova JL. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol. 2012;130(5):1019–27.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    McManus BA, McGovern E, Moran GP, Healy CM, Nunn J, Fleming P, et al. Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral candidiasis without culture evidence. J Clin Microbiol. 2011;49(5):1879–89.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Meager A, Visvalingam K, Peterson P, Möll K, Murumagi A, Krohn K, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3(7):e289.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008;93(11):4389–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Meloni A, Willcox N, Meager A, Atzeni M, Wolff SA, Husebye ES, et al. Autoimmune polyendocrine syndroma type 1: an extensive longitudinal study in Sardinian patients. J Clin Endocrinol Metab. 2012;97(4):1114–24.PubMedCrossRefGoogle Scholar
  20. 20.
    Myhre AG, Halonen M, Eskelin P, Ekwall O, Hedstrand H, Rorsman F, et al. Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clin Endocrinol. 2001;54:211–7.CrossRefGoogle Scholar
  21. 21.
    Negi VS, Elluru S, Sibéril S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27(3):233–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison’s disease with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore). 1981;60(5):355–62.CrossRefGoogle Scholar
  23. 23.
    Ng WF, von Delwig A, Carmicheal AJ, Arkwright PD, Abinun M, Cant AJ, et al. Impaired TH 17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol. 2010;126(5):1006–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Perniola R, Falorni A, Clemente MG, Forini F, Accoqli E, Lobreqlio G. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dytrophy (APECED). Eur J Endocrinol. 2000;143(4):497–503.PubMedCrossRefGoogle Scholar
  26. 26.
    Peterson P, Pitkanen J, Sillanpaa N, Krohn K. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: a model disease to study molecular aspects of endocrine autoimmunity. Clin Exp Immunol. 2004;135:348–57.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Puel A, Cypowyj S, Maródi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol. 2012;12(6):616–22.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291–7.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr Opin Immunol. 2010;22(4):467–74.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Rautemaa R, Hietanen J, Nissalo S, Pirinen S, Perheentupa J. Oral and oesophageal squamous cell carcinoma—a complication or a component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol. 2007;43:607–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and eosophageal cancer. Med Mycol. 2008;46(1):85–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titer to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol. 2002;105(2):192–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Sibéril S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, et al. Intravenous immunoglobulins in autoimmune and inflammatory disease. Ann N Y Acad Sci. 2007;1110:497–506.PubMedCrossRefGoogle Scholar
  34. 34.
    Thorpe ES, Handley HE. Chronic tetany and chronic mycelial stomatitis in a child aged four and one-half years. Arch Pediatr Adolesc Med. 1929;38(2):328–38.CrossRefGoogle Scholar
  35. 35.
    Tóth B, Méhes L, Taskó S, Szalai Z, Tulassay Z, Cypowyj S, et al. Herpes in STAT1 gain-of-function mutation. Lancet. 2012;379(9835):2500.PubMedCrossRefGoogle Scholar
  36. 36.
    Tóth B, Wolff AS, Halász Z, Tar A, Szüts P, Illyés I, et al. Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy. Clin Endocrinol (Oxf). 2010;72(5):641–7.CrossRefGoogle Scholar
  37. 37.
    Uittamo J, Siikala E, Kaihovaara P, Salaspuro M, Rautemaa R. Chronic candidosis and oral cancer in APECED-patients: production of carcinogenic acetaldehyde from glucose and ethanol by Candida albicans. Int J Cancer. 2009;124:754–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Weiler FG, Dias-da-Silva MR, Lazaretti-Castro M. Autoimmune polyendocrine syndrome type 1: case report and review of literature. Arg Bras Endocrinol Metabol. 2012;56(1):54–66.Google Scholar
  39. 39.
    Zelante T, Iannitti R, De Luca A, Romani L. IL-22 in antifungal immunity. Eur J Immunol. 2011;41(2):270–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Adrien Katalin Sarkadi
    • 1
  • Szilvia Taskó
    • 1
  • Gabriella Csorba
    • 1
  • Beáta Tóth
    • 1
  • Melinda Erdős
    • 1
    Email author
  • László Maródi
    • 1
  1. 1.Department of Infectious and Pediatric ImmunologyUniversity of Debrecen, Medical and Health Science CenterDebrecenHungary

Personalised recommendations